UMB Bank n.a. Has $230,000 Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX)

UMB Bank n.a. lifted its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 73.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,479 shares of the medical research company’s stock after acquiring an additional 625 shares during the quarter. UMB Bank n.a.’s holdings in Quest Diagnostics were worth $230,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of DGX. Van Lanschot Kempen Investment Management N.V. acquired a new position in Quest Diagnostics during the second quarter worth $48,783,000. M&G Plc acquired a new position in shares of Quest Diagnostics during the 1st quarter worth about $46,432,000. Vanguard Group Inc. raised its holdings in shares of Quest Diagnostics by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock valued at $1,853,151,000 after purchasing an additional 345,754 shares during the period. Wedge Capital Management L L P NC lifted its stake in Quest Diagnostics by 601.7% in the 2nd quarter. Wedge Capital Management L L P NC now owns 277,561 shares of the medical research company’s stock valued at $37,993,000 after purchasing an additional 238,007 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Quest Diagnostics by 222.0% during the second quarter. Point72 Asset Management L.P. now owns 299,740 shares of the medical research company’s stock worth $41,028,000 after purchasing an additional 206,640 shares during the period. Institutional investors own 88.06% of the company’s stock.

Insider Buying and Selling

In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of Quest Diagnostics stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total value of $60,093.60. Following the transaction, the senior vice president now owns 5,019 shares in the company, valued at $718,118.52. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,990 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the sale, the senior vice president now owns 11,459 shares in the company, valued at $1,756,206.34. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mark E. Delaney sold 420 shares of the company’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total transaction of $60,093.60. Following the transaction, the senior vice president now owns 5,019 shares of the company’s stock, valued at $718,118.52. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.79% of the stock is owned by corporate insiders.

Quest Diagnostics Trading Up 0.6 %

DGX opened at $148.67 on Friday. The stock has a market capitalization of $16.55 billion, a price-to-earnings ratio of 20.06, a P/E/G ratio of 2.45 and a beta of 0.89. The company has a quick ratio of 0.91, a current ratio of 1.00 and a debt-to-equity ratio of 0.57. Quest Diagnostics Incorporated has a twelve month low of $120.10 and a twelve month high of $159.36. The company has a 50-day simple moving average of $152.51 and a 200 day simple moving average of $143.34.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.31 by $0.04. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.30 EPS. Analysts predict that Quest Diagnostics Incorporated will post 8.89 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.75 per share. The ex-dividend date is Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 2.02%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 40.49%.

Wall Street Analyst Weigh In

Several research firms have issued reports on DGX. Evercore ISI started coverage on Quest Diagnostics in a research note on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price objective on the stock. Truist Financial raised their price target on Quest Diagnostics from $158.00 to $165.00 and gave the company a “hold” rating in a report on Monday, October 7th. Barclays upped their price objective on shares of Quest Diagnostics from $144.00 to $154.00 and gave the company an “equal weight” rating in a report on Tuesday, August 27th. Robert W. Baird raised their target price on shares of Quest Diagnostics from $153.00 to $154.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, StockNews.com downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Monday, October 7th. Ten analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Quest Diagnostics has a consensus rating of “Hold” and a consensus target price of $154.92.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.